AI is revolutionizing pharmaceuticals, moving from a side tool to a core driver of many aspects of the industry. Eli Lilly is leading the way, appointing Thomas Fuchs as its first Chief AI Officer to integrate AI across its pipeline. A NASA and Mount Sinai veteran, Fuchs is turning Lilly’s data into a competitive edge. He joins Inside the ICE House to share how Lilly is building the AI-powered medicine company of the future.
Up Next in 2025 | Inside the ICE House
-
Alto Neuroscience CEO Dr. Amit Etkin ...
The future of mental health is being transformed, moving beyond trial-and-error treatments to science-driven precision. Breakthroughs in neuroscience, AI, and precision medicine are mapping the brain’s unique biological signatures, creating pathways for personalized care. Alto Neuroscience is at ...
-
AI, Ambition, and Innovation with Hum...
Artificial intelligence is reshaping industries by unlocking insights hidden within massive amounts of unstructured data. With powerful tools like vector databases and enterprise platforms, AI is driving breakthroughs across healthcare, finance, and entertainment. Pinecone founder Edo Liberty and...
-
W&T Offshore CEO Tracy Krohn on Steer...
The offshore oil and gas industry fuels progress by unlocking hidden energy reserves deep beneath the ocean’s surface. With advanced technology, it thrives in some of the world’s harshest environments to power industries, transportation, and daily life. W&T Offshore has been a leader in this spac...
